Foghorn Therapeutics Inc. (FHTX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Foghorn Therapeutics is a clinical-stage biopharmaceutical company developing medicines targeting the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company is currently advancing FHD-286 in Phase 1 trials for acute myeloid leukemia and has submitted an IND for FHD-909. Foghorn operates as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Collaboration Revenue | $6,888 | $5,599 | $11,938 | $10,908 |
| Net Loss | $(22,979) | $(29,487) | $(47,995) | $(59,975) |
| Net Loss Per Share (Basic/Diluted) | $(0.45) | $(0.70) | $(1.02) | $(1.43) |
| Operating Expenses | $33,520 | $37,649 | $66,764 | $76,275 |
| Cash & Cash Equivalents | $138,947 | $57,703 | $138,947 | $57,703 |
| Marketable Securities | $146,230 | $130,160 | $146,230 | $130,160 |
| Total Liquidity (Cash + Securities) | $285,177 | $187,863 | $285,177 | $187,863 |
| Deferred Revenue | $290,726 | $268,115 | $290,726 | $268,115 |
Note: Revenue is derived entirely from collaboration agreements, primarily with Eli Lilly. There are no product sales.
Material Changes vs. Prior Period
- Capital Raise: In May 2024, the company completed an offering of common stock and pre-funded warrants, raising net proceeds of $102.8 million. This significantly improved liquidity compared to the prior year.
- Expense Reduction: Operating expenses decreased by approximately 11% year-over-year for the six-month period. This was driven by a reduction in headcount and the shutdown of the Phase 1 clinical trial for FHD-609.
- Impairment Charge: The company recorded a non-cash impairment charge of $2.4 million related to the sublease of office space in Cambridge, MA. This was a new expense item not present in the prior year.
- Revenue Recognition: Collaboration revenue increased slightly, driven by continued work under the Lilly Collaboration Agreement, offset by the termination of the Merck Collaboration Agreement in late 2023.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash, cash equivalents, and marketable securities ($285.2 million) to fund operations for at least 12 months from the filing date.
- Pipeline Progress: The company is conducting a Phase 1 dose escalation study for FHD-286 in acute myeloid leukemia. A Phase 1 study for FHD-909 (partnered with Lilly) is anticipated to start later in 2024.
- Cost Sharing: Following the transition of FHD-909 to Lilly, the company shares 50% of development costs for this program until registrational trials.
- Risks: The company has an accumulated deficit of $519.6 million and expects to continue incurring losses. Future success depends on clinical trial results, regulatory approvals, and the ability to raise additional capital. Risks include the potential inability to secure funding on acceptable terms and the inherent uncertainties of drug development.
Key Facts for Investor Verification
- Cash Runway: Verify the $285.2 million liquidity position and the 12-month burn rate projection given the recent capital raise.
- Revenue Sustainability: Confirm the timing and magnitude of future revenue recognition from the $290.7 million deferred revenue balance associated with the Lilly agreement.
- Clinical Milestones: Monitor the initiation of the FHD-909 Phase 1 trial and the progression of the FHD-286 trial in acute myeloid leukemia.
- Expense Management: Assess whether the reduction in R&D expenses (due to headcount cuts and trial shutdowns) impacts the ability to advance remaining pipeline assets.
- Dilution: Review the impact of the May 2024 offering (12.7 million shares + 7.2 million pre-funded warrants) on existing shareholder equity.